Cambridge, Mass. — August 26, 2025 — Leads & Copy — Immuneering Corporation (Nasdaq: IMRX) announced the closing of a private placement to institutional and accredited investors, raising approximately $25 million before fees. The company sold unregistered shares of Class A common stock and accompanying purchase warrants. The offering was exempt from registration under the Securities Act of 1933.
Leerink Partners acted as a financial advisor for the private placement. Immuneering is a clinical-stage oncology company focused on developing cancer medicines, including atebimetinib (IMM-1-104), currently in a Phase 2a trial.
The company is also developing Deep Cyclic Inhibitors, with its lead product candidate in Phase 2a trials for advanced solid tumors.
Gina Nugent, Media Contact, Gina.nugent.external@immuneering.com
Laurence Watts, Investor Contact, 619-916-7620, laurence@newstreetir.com
Source: Immuneering Corporation
